Effects of prostaglandin E1 on hepatic blood flow in conscious dogs with chronic biliary obstruction. 1998

Y Machiki, and U Nimura, and H Kanda, and T Uematsu, and Y U Kitagawa, and S Kamiya, and T Watanabe
First Department of Surgery, Nagoya University School of Medicine, Japan.

To evaluate the effects of prostaglandin E1 (PGE1) on the hepatic circulation in cholestasis, hepatic arterial blood flow (HAP), portal venous blood flow (PVF), cardiac output, and heart rate during PGE1 infusions were investigated before and 2 weeks after biliary obstruction in conscious dogs by a transit-time ultrasonic flowmeter. In the control period, HAF and PVF increased dose dependently with the infusion of PGE1 from 0.05 to 0.5 micrograms/kg/min. During the biliary obstruction period, a lower dose of PGE1 increased HAF and PVF. The plasma concentration level of PGE1 during the infusion of PGE1 was significantly higher at each dose in the cholestatic animals. These results suggest that the metabolism of PGE1 is attenuated by cholestasis. Plasma PGE1 concentrations should be useful in deciding the optimal dose of PGE1.

UI MeSH Term Description Entries
D008102 Liver Circulation The circulation of BLOOD through the LIVER. Hepatic Circulation,Circulation, Liver,Circulation, Hepatic
D008297 Male Males
D002302 Cardiac Output The volume of BLOOD passing through the HEART per unit of time. It is usually expressed as liters (volume) per minute so as not to be confused with STROKE VOLUME (volume per beat). Cardiac Outputs,Output, Cardiac,Outputs, Cardiac
D002779 Cholestasis Impairment of bile flow due to obstruction in small bile ducts (INTRAHEPATIC CHOLESTASIS) or obstruction in large bile ducts (EXTRAHEPATIC CHOLESTASIS). Bile Duct Obstruction,Biliary Stasis,Bile Duct Obstructions,Biliary Stases,Cholestases,Duct Obstruction, Bile,Duct Obstructions, Bile,Obstruction, Bile Duct,Obstructions, Bile Duct,Stases, Biliary,Stasis, Biliary
D002908 Chronic Disease Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2). Chronic Condition,Chronic Illness,Chronically Ill,Chronic Conditions,Chronic Diseases,Chronic Illnesses,Condition, Chronic,Disease, Chronic,Illness, Chronic
D004195 Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases. Animal Disease Model,Animal Disease Models,Disease Model, Animal
D004285 Dogs The domestic dog, Canis familiaris, comprising about 400 breeds, of the carnivore family CANIDAE. They are worldwide in distribution and live in association with people. (Walker's Mammals of the World, 5th ed, p1065) Canis familiaris,Dog
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D005260 Female Females
D000527 Alprostadil A potent vasodilator agent that increases peripheral blood flow. PGE1,Prostaglandin E1,Caverject,Edex,Lipo-PGE1,Minprog,Muse,PGE1alpha,Prostaglandin E1alpha,Prostavasin,Prostin VR,Prostine VR,Sugiran,Vasaprostan,Viridal,Lipo PGE1

Related Publications

Y Machiki, and U Nimura, and H Kanda, and T Uematsu, and Y U Kitagawa, and S Kamiya, and T Watanabe
January 1973, Pharmacology,
Y Machiki, and U Nimura, and H Kanda, and T Uematsu, and Y U Kitagawa, and S Kamiya, and T Watanabe
June 2001, Journal of clinical anesthesia,
Y Machiki, and U Nimura, and H Kanda, and T Uematsu, and Y U Kitagawa, and S Kamiya, and T Watanabe
May 1982, Masui. The Japanese journal of anesthesiology,
Y Machiki, and U Nimura, and H Kanda, and T Uematsu, and Y U Kitagawa, and S Kamiya, and T Watanabe
May 1970, The Journal of surgical research,
Y Machiki, and U Nimura, and H Kanda, and T Uematsu, and Y U Kitagawa, and S Kamiya, and T Watanabe
December 1996, The Journal of surgical research,
Y Machiki, and U Nimura, and H Kanda, and T Uematsu, and Y U Kitagawa, and S Kamiya, and T Watanabe
March 1996, General pharmacology,
Y Machiki, and U Nimura, and H Kanda, and T Uematsu, and Y U Kitagawa, and S Kamiya, and T Watanabe
April 1976, Japanese journal of pharmacology,
Y Machiki, and U Nimura, and H Kanda, and T Uematsu, and Y U Kitagawa, and S Kamiya, and T Watanabe
December 1992, Zhonghua wai ke za zhi [Chinese journal of surgery],
Y Machiki, and U Nimura, and H Kanda, and T Uematsu, and Y U Kitagawa, and S Kamiya, and T Watanabe
April 1968, Gastroenterology,
Y Machiki, and U Nimura, and H Kanda, and T Uematsu, and Y U Kitagawa, and S Kamiya, and T Watanabe
August 1986, The Journal of pharmacology and experimental therapeutics,
Copied contents to your clipboard!